MarginsXMarginsX
Home › Markets › Health Care › OKUR

OnKure Therapeutics Inc. (OKUR)

OKUR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.75
+4.56% on the day
Market cap
$111.4M
Micro cap
Revenue · 2024
$0
No prior year to compare
Net income · 2024
-$52.7M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/0000950170-25-036252-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerOKUR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001637715
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2024

LineValue
Revenue$0
Net income-$52.7M
Operating income-$54.4M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$110.8M
Total assets$114.9M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
38.0 months
$151.4M cash at September 30, 2026
Share count, 1 year
See the dilution note
+1115.9% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$6K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist."
10-Q 2026-11-04
Cash and burn$151.4M cash; operating cash flow -$12.0M a quarter.Report 2026-09-30
Shares outstanding40,503,094 (2026-11-02); 33,311,787 three years earlier. 3y figure adjusted for split (1-for-10 overall).Cover page 2026-11-02
Reverse splits, 3 years1; latest 1-for-10 on 2024-10-07Source 2024-10-07
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-08-04
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Denver, Colorado, United StatesPCAOB Form AP 2026-03-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $6K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$17.8M-$13.1M$151.4MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
Not filed-$15.3M-$10.4M$166.5MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2026
2026-03-31
Not filed-$15.2M-$12.9M$192.1MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2025
2025-12-31
Not filed-$13.5M-$11.5M$59.0MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q3 2025
2025-09-30
Not filed-$14.7M-$13.0M$70.3MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
Not filed-$15.4M-$13.3M$83.4MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2025
2025-03-31
Not filed-$15.9M-$14.0M$96.7MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2024
2024-12-31
Not filed-$17.4M-$23.4M$110.8MNo debt tags$010-Q 2025-11-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-04
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 405 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.2%
1 month+12.2%
3 months-32.6%
Year to date-9.3%
1 year-16.2%
From 52-week high-50.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CATXPerspective Therapeutics Inc.$0.9238-2.05%$111.6M
NERVMinerva Neurosciences Inc$2.20-4.35%$109.6M
PDSBPDS Biotechnology Corporation$0.9241+5.90%$113.4M
IMUXImmunic Inc.$7.23-3.86%$114.8M
FHTXFoghorn Therapeutics Inc.$1.79-13.53%$107.3M
BGMBGM Group Ltd.$8.01+1.71%$107.0M
ADAGAdagene Inc.$1.60-6.43%$105.7M
UPBUpstream Bio Inc.$2.15-22.66%$117.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier